A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2025-06-03
Target enrollment:
Participant gender:
Summary
This is a Phase 1, multicenter, open label, study of CC-95266 in subjects with relapsed
and/or refractory multiple myeloma. The study will consist of two parts: dose escalation
(Part A) and dose expansion (Part B).
The dose escalation (Part A) of the study will evaluate the safety and tolerability of
increasing doses of CC-95266 in a single administration to establish a maximum tolerated dose
(MTD) and/or recommended Phase 2 dose (RP2D), and the dose expansion (Part B) of the study
will further evaluate the safety, pharmacokinetics (PK)/ pharmacodynamics (PD), and efficacy
of CC-95266 at the RP2D.